Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel

April 28, 2026 09:20 AM EDTUpdated 01:28 PM DealsPharma Up­dat­ed: Ab­b­Vie flirts with pop­u­lar pan-RAS field in up to $1.45B op­tion to ac­quire Kestrel Kyle LaHucik Biotech Correspondent The pan-RAS space con­tin­ues to gain mo­men­tum, as Ab­b­Vie signs up for a shot at en­ter­ing a field with the po­ten­tial to dras­ti­cal­ly al­ter the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER